Frank Waddell

Johnson & Johnson: The Elephant in the Merck-Schering Living Room

This is a big issue that seems to garner little attention at the moment for JNJ. It is a heads i win, tails i don't lose anything scenario for JNJ. They have a pretty large free call option on the results of the arbitration with Schering-Plough/Merck.

JNJ 3Q: Misses on Revenue, and that Should Be a Concern

Meaningless?? Uh...When half of your earnings come from abroad (non-dollar denominated currency) if the dollar falls lower, JNJ's earnings increase by a huge amount. It is hardly meaningless. The dollars woes are JNJ's (and other large multinationals) gains.